Clinical trial
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma…
NCT00003293 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00003293 |
|---|---|
| Title | SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme |
| Official title | A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | leflunomide, procarbazine hydrochloride |
| Start date | Feb 1, 1998 |
| Primary completion | May 1, 2001 |
| Completion | May 1, 2001 |
| First posted | Jun 3, 2004 |
| Last update posted | Sep 11, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: